Dr. Claire F. Verschraegen

Dr. Claire F. Verschraegen M.D

Director, Hematology/Oncology Division Department of Medicine

(802) 656-5487
N/A
UVM Given College of Medicine Building, 89 Beaumont Avenue, Suite E-214, Burlington, VT 05405, USA

Dr. Claire F. Verschraegen is a professor of medicine at the Division of Hematology Oncology and Director of the Translational Therapeutics and Phase I program at the University of New Mexico Cancer Research and Treatment Center.

Dr. Verschraegen is a member of the Education Committee of the International Gynecological Cancer Society. Presently, she is the Director of the Clinical Trial Office and one of the Investigational Drug Program Coordinators at the Cancer Research and Treatment Center of the University of New Mexico.

Her clinical interests include hematology, peritoneal mesothelioma, and oncology.

Education and Training

Dr. Claire F. Verschraegen graduated Magna Cum Laude, in 1982, at the Universite Libre de Bruxelles, in Belgium. She also completed the Internship and residency in Oncology Department at the Univeriste Libre in Belgium. Along with her work training at Universite Libre de Bruxelles, Dr. Verschraegen completed a residency and fellowship stateside at the University of Texas, her residency lasted from 1988 to 1991 and was in internal medicine, while her fellowship focused on oncology in 1994.

Dr. Verschraegen is Board Certified in both Medical Oncology and Internal Medicine, with specialties in hematology and oncology. She is also certified internationally under the Belgian Department of Human Health.

Along with mesothelioma, Dr. Verschraegen conducts research involving the application of emerging chemotherapy drugs, namely Alimta, in conjunction with other drugs and methods, for the treatment of peritoneal mesothelioma and other varieties of cancer.

Awards and Dinstinctions

Dr. Verschraegen is a member of the Gynecologic Cancer Society, and a Fulbright scholar, as well as the recipient of the Occino-Kernkamp Prize from the Belgium Association of University Women. She is considered an expert in the field of peritoneal mesothelioma, appearing as a keynote speaker for symposiums, conferences, and workshops of the same topic and other types and histology of mesothelioma.

Reference: